Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
复制标题
DOI：
10.1002/acr2.11299
复制
发表时间：
2021-09
影响因子：
3.4
通讯作者：
Troldborg A
中科院分区：
文献类型：
--
作者：
Ammitzbøll C;Bartels LE;Bøgh Andersen J;Risbøl Vils S;Elbaek Mistegård C;Dahl Johannsen A;From Hermansen ML;Kragh Thomsen M;Erikstrup C;Hauge EM;Troldborg A
辉瑞 BioNTech BNT162b2 (BNT162b2) 的疫苗预防 2019 年冠状病毒病 (COVID-19) 的有效性为 95%，是第一个获得批准的针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的疫苗。然而，免疫抑制治疗是获得批准的 3 期试验的排除标准。因此，将试验结果外推到接受免疫抑制药物治疗的风湿性疾病患者时需要谨慎。系统性红斑狼疮 (SLE；n = 61) 和类风湿性关节炎 (RA；n = 73) 患者被纳入 COPANARD（新冠大流行性自身免疫性风湿病）队列，自 COVID-19 大流行开始以来一直进行跟踪。患者在 2020 年 12 月至 2021 年 4 月期间接受了 BNT162b2 疫苗。所有患者在接种疫苗前和第二次接种疫苗后 1 周均测量了针对 SARS-CoV-2 的总抗体（VITROS 免疫诊断产品）。在 134 名患者（中位年龄 70 岁）中，77% 的患者能够对疫苗产生可检测到的血清学反应。在接受利妥昔单抗治疗的患者中，只有 24% 的患者在接种疫苗后血清中可检测到抗 SARS-CoV-2 抗体。自上次利妥昔单抗治疗以来的时间似乎并未影响疫苗反应。在调整治疗时，RA 或 SLE 患者之间没有观察到显着差异，并且未检测到抗体水平与年龄之间的相关性（r = -0.12；P = 0.18）。 RA 和 SLE 患者注射两剂 BNT162b2 疫苗后针对 SARS-CoV-2 的抗体测量表明，23% 的患者无法对疫苗产生可检测的血清学反应。 B 细胞耗竭疗法 (BCDT) 值得特别关注，我们的研究结果呼吁特别关注接受 BCDT 的患者。
With a vaccine effectiveness of 95% for preventing coronavirus disease 2019 (COVID‐19), Pfizer‐BioNTech BNT162b2 (BNT162b2) was the first vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) to be approved. However, immunosuppressive therapy was an exclusion criterion in the phase 3 trial that led to approval. Thus, extrapolation of the trial results to patients with rheumatic diseases treated with immunosuppressive drugs warrants caution. Patients with systemic lupus erythematosus (SLE; n = 61) and rheumatoid arthritis (RA; n = 73) were included from the COPANARD (Corona Pandemic Autoimmune Rheumatic Disease) cohort, followed since the beginning of the COVID‐19 pandemic. Patients received the BNT162b2 vaccine between December 2020 and April 2021. All patients had total antibodies against SARS‐CoV‐2 measured before vaccination and 1 week after the second vaccination (VITROS Immunodiagnostic Products). Of 134 patients (median age, 70 years), 77% were able to mount a detectable serological response to the vaccine. Among patients treated with rituximab, only 24% had detectable anti–SARS‐CoV‐2 antibodies in their serum after vaccination. The time since the last rituximab treatment did not seem to influence the vaccine response. No significant difference was observed between patients with RA or SLE when adjusting for treatment, and no correlation between antibody levels and age was detected (r = −0.12; P = 0.18). Antibody measurements against SARS‐CoV‐2 in patients with RA and SLE after two doses of the BNT162b2 vaccine demonstrated that 23% of patients could not mount a detectable serological response to the vaccine. B cell–depleting therapy (BCDT) is of specific concern, and our findings call for particular attention to the patients receiving BCDT.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
影响因子：
27.4
作者：
Park, Jin Kyun;Lee, Yun Jong;Lee, Eun Bong
通讯作者：
Lee, Eun Bong
影响因子：
6.2
作者：
Marques CDL;Kakehasi AM;Pinheiro MM;Mota LMH;Albuquerque CP;Silva CR;Santos GPJ;Reis-Neto ET;Matos P;Devide G;Dantas A;Giorgi RD;Marinho AO;Valadares LDA;Melo AKG;Ribeiro FM;Ferreira GA;Santos FPS;Ribeiro SLE;Andrade NPB;Yazbek MA;Souza VA;Paiva ES;Azevedo VF;Freitas ABSB;Provenza JR;Toledo RA;Fontenelle S;Carneiro S;Xavier R;Pileggi GCS;Reis APMG
通讯作者：
Reis APMG
影响因子：
3.9
作者：
Bachiller-Corral, Javier;Boteanu, Alina;Vazquez-Diaz, Monica
通讯作者：
Vazquez-Diaz, Monica